A cytologic study of an occupational cohort at increased risk for bladder cancer was conducted. The cohort consisted of 542 workers who were potentially exposed to beta-naphthylamine (91598), benzidine (92875), alpha-naphthylamine (134327), and o-toluidine (119937) between 1949 and 1972 at a dye intermediary production facility at Augusta, Georgia. A previous study had found an excess risk of bladder cancer in the cohort. Two urine samples were collected from each subject for a urine cytology examination. The cytological findings were classified as positive, suspicious, atypical, or negative. Subjects with positive, suspicious, or atypical cytologies were referred to a urology clinic for diagnostic study which included repeat urinalyses for cytological examination, bladder washings analysis, cytoscopy, and multiple directed and random bladder biopsies. Six subjects had positive and two suspicious urine cytologies. One of the positive subjects had a previous history of bladder cancer. Biopsies indicated invasive carcinoma or in-situ nonpapillary carcinoma in five positive subjects. Severe atypia was found in the sixth subject. No significant abnormalities were found in the two subjects with suspicious cytological findings. Fifty six subjects had atypical urine cytologies. Fifty three of these were diagnosed from urine samples only; the other three required bladder washings. A total of 165 single and multiple biopsies were performed on these subjects. Of these, three had normal urothelium or hyperplasia, 11 atypia, one had carcinoma in-situ, and one had a noninfiltrating papillary carcinoma. A total of 477 subjects had normal cytological findings. One of these developed symptoms 5 months later. Biopsy revealed a papillary transitional cell carcinoma invading the lamina propria. The authors conclude that close observation of the cohort is indicated as the workers can be expected to develop more cancers in the future.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.